China Resources Shuanghe Clindamycin Phosphate Injection Passes Consistency Evaluation of Generic Drugs

On February 16, China Resources Shuanghe announced that its wholly-owned subsidiary Shuanghe Limin had received the “Approval Notice for Supplementary Drug Application” (Notice No.

Clindamycin phosphate is a derivative of clindamycin, which has no antibacterial activity in vitro.

Shuanghe Limin started the consistency evaluation of the drug in 2019, submitted the application for consistency evaluation to the State Food and Drug Administration on December 29, 2020, and received the acceptance notice on January 6, 2021.

As of the date of this announcement, the cumulative R&D investment of Shuanghe Limin on the consistency evaluation of the drug was RMB 6,006,700 (unaudited)

Clindamycin Phosphate Injection was developed by Pharmacia and Upjohn Co (a subsidiary of Pfizer) under the trade name Cleocin Phosphate and was approved in the United States in 1972

The sales revenue of Shuanghe Limin in 2020 is 41.